Phase I trial of elactocin.
Phase I trial of elactocin.
复制标题
DOI：
10.1038/bjc.1996.415
复制
发表时间：
1996-08
影响因子：
8.8
通讯作者：
Brampton, MH
中科院分区：
文献类型：
--
作者：
Newlands, ES;Rustin, GJS;Brampton, MH
Elactocin是一种新型抗肿瘤抗生素，在体外对一系列肿瘤具有强效活性。这一第一阶段的试验elactocin确定的剂量限制性毒性为严重的厌食症和不适。使用的时间表包括每周输注1小时3次、每周输注24小时3次、每天输注1小时x5（每周3次）、每周输注1小时和最后连续5天静脉输注。在所有这些方案中，剂量限制性毒性是相同的，由于未发现部分或完全缓解，我们不建议进行进一步的elactocin试验。
Elactocin is a novel anti-tumour antibiotic which has potent activity in vitro against a range of tumours. This phase I trial of elactocin identified the dose-limiting toxicity as profound anorexia and malaise. The schedules used included 1 h infusion 3 weekly, 24 h infusion 3 weekly, 1 h infusion daily x 5 (3 weekly), 1 h infusion weekly and finally continuous 5 day intravenous infusion. On all these schedules dose-limiting toxicity was the same and as no partial or complete responses were identified, we do not recommend that further trials of elactocin are performed.
影响因子：
3.3
作者：
TUNAC, JB;GRAHAM, BD;LENZINI, MD
通讯作者：
LENZINI, MD